SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[X] Soliciting Material Under Rule 14a-12
DYNACARE INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
- --------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
- --------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined):
- --------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
- --------------------------------------------------------------------------------
(5) Total fee paid:
- --------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials:
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
- --------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
- --------------------------------------------------------------------------------
(3) Filing Party:
- --------------------------------------------------------------------------------
(4) Date Filed:
- --------------------------------------------------------------------------------
DYNACARE INC.
FOR IMMEDIATE RELEASE
---------------------
CONTACT:
DYNACARE INC.
Zbig Biskup
Chief Financial Officer
972-387-3200
DYNACARE ANNOUNCES EXPIRATION OF ANTITRUST WAITING PERIOD
WITH RESPECT TO TRANSACTION WITH LABCORP
DALLAS, TX, JUNE 20, 2002 -- Dynacare Inc. (Nasdaq: DNCR, TSE: DNA) today
announced that the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act with respect to Laboratory Corporation of America Holding's
(NYSE: LH) proposed acquisition of all outstanding shares of common stock of
Dynacare expired at 11:59 PM, New York City time, on June 19, 2002.
This transaction remains subject to various conditions including regulatory
approval in Canada and approval of Dynacare's shareholders. It is expected that
this transaction will close in the third quarter of 2002.
Through its integrated network of regional laboratory operations, Dynacare
provides innovative and trusted clinical laboratory services to its clients,
their patients and professional partners. Dynacare provides laboratory services
in 21 U.S. states and is a leading provider of laboratory services in Canada.
This press release may contain "forward-looking statements" within the meaning
of Section 21E of the Securities Exchange Act of 1934. When used in this press
release, the words "may," "could," "should," "would," "believe," "anticipate,"
"estimate," "expect," "intend," "plan" and similar expressions or statements
regarding future periods are intended to identify forward-looking statements.
All forward-looking statements are inherently uncertain as they are based on
various expectations and assumptions concerning future events, which by their
nature involve substantial risks and uncertainties beyond Dynacare Inc.'s
control. Dynacare Inc. undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after the date on which
such statement is made. Dynacare Inc. cannot assess the impact of or the extent
to which any single factor or risk, or combination of them, may cause actual
results to differ materially from those contained in any forward-looking
statements. For a more complete discussion of risk factors, please see Dynacare
Inc.'s filings with the Securities and Exchange Commission, including its Annual
Report on Form 10K for the year ended December 31, 2001.
Security holders of Dynacare Inc. are urged to read the proxy statement
regarding the proposed Plan of Arrangement when it is finalized and distributed
to security holders because it will contain important information for making an
informed decision. The definitive proxy statement will be filed with the U.S.
Securities and Exchange Commission (the "SEC") by Dynacare, and security holders
may obtain a free copy of such proxy statement when it becomes available, and
other documents filed with the SEC by Dynacare, at the SEC's website at
www.sec.gov. The definitive proxy statement, when it becomes available, and
other documents filed by Dynacare, may also be obtained free of charge by
directing a request to Dynacare Inc., 14900 Landmark Boulevard, Suite 200,
Dallas, Texas 75254, attention: Zbig S. Biskup, Executive Vice President and
Chief Financial Officer and Secretary.
Dynacare and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the security holders of
Dynacare in favor of the transaction. The directors and executive officers of
Dynacare and their beneficial ownership of Dynacare common stock as of April 15,
2002 are set forth in the proxy statement for the 2002 annual meeting filed by
Dynacare on April 30, 2002. LabCorp and its directors and executive officers may
be deemed to be participants in the solicitation of proxies from the security
holders of Dynacare in favor of the transaction. The directors and executive
officers of LabCorp are set forth in the proxy statement for the 2002 annual
meeting filed by LabCorp on April 15, 2002. Security holders of Dynacare may
obtain additional information regarding the interests of such participants by
reading the definitive proxy statement.
###